Abstract: Hybrid tomato variety ‘H1657’ is described. The tomato variety is a ground-culture hybrid tomato variety suitable for machine harvest, and is adaptable to the climactic conditions of regions such as California (USA), Ontario (Canada), Australia, Portugal, Spain, and Italy.

Abstract: Hybrid tomato variety ‘H1301’ is described. The ‘H1301’ tomato variety is a ground-culture hybrid tomato variety suitable for machine harvest.

Abstract: Hybrid tomato variety ‘H1651’ is described. The tomato variety is a ground-culture hybrid tomato variety suitable for machine harvest, and is adaptable to the climactic conditions of regions such as California (USA), Ontario (Canada), Australia, Portugal, Spain, and Italy.

Abstract: Hybrid tomato variety ‘H1310” is described. The ‘H1310’ tomato variety is a ground-culture hybrid tomato variety suitable for machine harvest.

Abstract: Hybrid tomato variety ‘H1307’ is described. The ‘H1307’ tomato variety is a ground-culture hybrid tomato variety suitable for machine harvest.

Abstract: The present invention features methods for treating or reducing the severity of a microbial infection in an infant of a lactating mother. Compositions comprising food products fermented by Lactobacillus paracasei CBA L74, International Depository Accession Number LMG P-24778 are administered to a pregnant or lactating mother in order to treat or attenuate the severity of a microbial infection in her offspring.

Abstract: The present application relates to compositions and methods for modulation of the mucosal immune system. The compositions include foods fermented by the probiotic organism, Lactobacillus paracasei CBA L74 (International Depository Accession Number LMG P-24778). Alternatively, the compositions can include L. paracasei CBA L74 and a physiologically acceptable carrier. In some embodiments, the L. paracasei CBA L74 can be non-replicating. The compositions can be administered to a subject having or at risk for gastrointestinal disorders related to immaturity of the immune system, infection or disease.

Abstract: The present invention features compositions and methods for treating gluten-related disorders. We describe compositions comprising one or more metabolites produced by Lactobacillus paracasei CBA L74, International Depository Accession Number LMG P-24778 that reduce cellular entry of gliadin peptides. The compositions may include a physiologically acceptable carrier, for example, a food product or a pharmaceutical carrier. The compositions can be administered to a subject having a gluten-related disorder, for example, celiac disease or gluten sensitivity.

Abstract: Hybrid tomato variety ‘H1538’ is described. The ‘H1538’ tomato variety is a field-culture hybrid tomato variety suitable for machine harvest.

Abstract: Hybrid tomato variety ‘H1546’ is described. The ‘H1546’ tomato variety is a field-culture hybrid tomato variety suitable for machine harvest.

Abstract: Hybrid tomato variety ‘H1428’ is described. The ‘H1428’ tomato variety is a ground-culture hybrid tomato variety suitable for machine harvest.

Abstract: The present invention features compositions and methods for modulation of the mucosal immune system. The compositions include foods fermented by the probiotic organism, Lactobacillus paracasei CBA L74 (International Depository Accession Number LMG P-24778). Alternatively the compositions can include L. paracasei CBA L74 and a physiologically acceptable carrier. In some embodiments, the L. paracasei CBA L74 can be non-replicating. The compositions can be administered to a subject having or at risk for gastrointestinal disorders related to immaturity of the immune system, infection or disease.

Abstract: The present invention features methods for treating or reducing the severity of a microbial infection in an infant of a lactating mother. Compositions comprising food products fermented by Lactobacillus paracasei CBA L74, International Depository Accession Number LMG P-24778 are administered to a pregnant or lactating mother in order to treat or attenuate the severity of a microbial infection in her offspring.

Abstract: Hybrid tomato variety ‘H1293” is described. The ‘H1293’ tomato variety is a ground-culture hybrid tomato variety suitable for machine harvest, and is adaptable to the climactic conditions of regions such as California, USA, and Italy.

Abstract: Hybrid tomato variety ‘H1311” is described. The ‘H1311’ tomato variety is a ground-culture hybrid tomato variety suitable for machine harvest.

Abstract: A retorted liquid soup concentrate package (of about 70 to 100 g contents) expressible from the package when opened and dilutable with boiling or near boiling water (at a dilution ratio water/concentrate of from 1.9:1 to 2.5:1) to a lump free ready to eat soup form at at least 55° C. (preferably 60 to 65° C.) and a target volume less than 400 mls (preferably 250-300 mls).

Abstract: Hybrid tomato variety ‘H1292’ is described. The ‘H1292’ tomato variety is a ground-culture hybrid tomato variety suitable for machine harvest, and is adaptable to the climactic conditions of regions such as California, USA, and Italy.

Abstract: A squeezable bottle includes a panel having at least one ornamental feature thereon. The panel includes a first facet having a length and a width and a second facet having a length and width. The lengths of the first and second facets extend in a direction generally parallel to a length of the squeezable bottle. The second facet is disposed adjacent to and defines a first interface with the first facet, and the first interface defines a first one of the at least one ornamental features. A generally planar surface of the first facet is disposed at an angle relative to a generally planar surface of the second facet such that the panel is reversibly deformable.

Abstract: The present invention features compositions and methods for treating gluten-related disorders. We describe compositions comprising one or more metabolites produced by Lactobacillus paracasei CBA L74, International Depository Accession Number LMG P-24778 that reduce cellular entry of gliadin peptides. The compositions may include a physiologically acceptable carrier, for example, a food product or a pharmaceutical carrier. The compositions can be administered to a subject having a gluten-related disorder, for example, celiac disease or gluten sensitivity.

Abstract: A container for condiments includes a container portion having generally planar bottom, a generally parallel flange, a discharge spout, and a sidewall extending between the bottom and the flange. A generally planar cover portion is secured to the flange by an adhesive such that there exists a non-bonded region between the cover and the flange. At least one section of the flange in the non-bonded region is bent downwardly away from the cover portion to form therebetween a finger-access gap. The sidewall includes a front portion disposed below the spout and extending downwardly with respect thereto. The sidewall front portion is configured to prevent the spout from becoming displaced upwardly in response to the sidewall front portion being contacted by the rear portion of another container in a package of the containers.